$1.06 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was 76.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACHN | Sell | ACHILLION PHARMACEUTICALS IN | $32,435,000 | -26.1% | 3,250,000 | -44.0% | 3.05% | +5.9% |
| DGX | Sell | QUEST DIAGNOSTICS INC | $30,340,000 | -53.0% | 500,000 | -54.5% | 2.85% | -32.6% |
| GERN | Sell | GERON CORP | $6,880,000 | -57.1% | 3,440,045 | -31.2% | 0.65% | -38.5% |
| ANGO | Sell | ANGIODYNAMICS INC | $5,003,000 | -20.1% | 364,630 | -5.0% | 0.47% | +14.4% |
| RPRX | Exit | REPROS THERAPEUTICS INC | $0 | – | -390,370 | -100.0% | -0.44% | – |
| TRNX | Exit | TORNIER N V | $0 | – | -573,655 | -100.0% | -0.88% | – |
| FURX | Exit | FURIEX PHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -1.39% | – |
| RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -630,000 | -100.0% | -1.40% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -656,900 | -100.0% | -1.66% | – |
| HAE | Exit | HAEMONETICS CORP | $0 | – | -1,000,000 | -100.0% | -2.31% | – |
| HRC | Exit | HILL ROM HLDGS INC | $0 | – | -893,223 | -100.0% | -2.43% | – |
| LH | Exit | LABORATORY CORP AMER HLDGS | $0 | – | -400,000 | -100.0% | -2.68% | – |
| THC | Exit | TENET HEALTHCARE CORP | $0 | – | -900,000 | -100.0% | -2.77% | – |
| HCA | Exit | HCA HOLDINGS INC | $0 | – | -900,000 | -100.0% | -3.32% | – |
| CYH | Exit | COMMUNITY BK SHS IND INC | $0 | – | -1,387,900 | -100.0% | -4.13% | – |
| V107SC | Exit | WELLPOINT INC | $0 | – | -700,000 | -100.0% | -4.94% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -1,500,000 | -100.0% | -19.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.